Phosphoinositide 3-Kinase Is Required for Process Outgrowth and Cell Polarization of Gastrulating Mesendodermal Cells, Current Biology, vol.13, issue.15, pp.1279-89, 2003. ,
DOI : 10.1016/S0960-9822(03)00505-0
PDGF signalling controls the migration of mesoderm cells during chick gastrulation by regulating N-cadherin expression, Development, vol.135, issue.21, pp.3521-3551, 2008. ,
DOI : 10.1242/dev.023416
Ptenb Mediates Gastrulation Cell Movements via Cdc42/AKT1 in Zebrafish, PLoS ONE, vol.348, issue.Pt 1, p.18702, 2011. ,
DOI : 10.1371/journal.pone.0018702.s006
The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines, Cancer Res, vol.63, issue.9, pp.2172-2180, 2003. ,
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma, Journal of Clinical Investigation, vol.117, issue.3, pp.719-748, 2007. ,
DOI : 10.1172/JCI30102DS1
AKT-ions with a TWIST between EMT and MET, Oncotarget, vol.7, issue.38, pp.62767-77, 2016. ,
DOI : 10.18632/oncotarget.11232
Targeting the phosphoinositide 3-kinase pathway in cancer, Nature Reviews Drug Discovery, vol.3, issue.8, pp.627-671, 2009. ,
DOI : 10.4049/jimmunol.175.5.2783
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005), Cancer, vol.11, issue.13, pp.2193-2200, 2015. ,
DOI : 10.1586/era.10.226
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079), Investigational New Drugs, vol.20, issue.22, pp.985-91, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-0868
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer, Scientific Reports, vol.109, issue.1, p.12122, 2015. ,
DOI : 10.1073/pnas.1204384109
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma, British Journal of Haematology, vol.116, issue.4, pp.463-70, 2015. ,
DOI : 10.1038/onc.2008.245
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.29, issue.35, pp.4688-95, 2011. ,
DOI : 10.1200/JCO.2011.35.5263
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors, Breast Cancer Research, vol.30, issue.6, p.110, 2013. ,
DOI : 10.1200/JCO.2011.35.6725
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours, British Journal of Cancer, vol.111, issue.10, pp.1932-1976, 2014. ,
DOI : 10.5966/sctm.2012-0096
A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study, Pediatric Blood & Cancer, vol.59, issue.7, pp.1246-51, 2014. ,
DOI : 10.1002/pbc.23412
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors, Cell Reports, vol.6, issue.2, pp.377-87, 2014. ,
DOI : 10.1016/j.celrep.2013.12.035
Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia, Clinical Cancer Research, vol.20, issue.8, pp.2226-2261, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-1978
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors, Journal of Hematology & Oncology, vol.7, issue.1, 2014. ,
DOI : 10.1158/1078-0432.CCR-08-0125
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors, Molecular Cancer Therapeutics, vol.14, issue.11, pp.2441-51, 2015. ,
DOI : 10.1158/1535-7163.MCT-15-0230
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Investigational New Drugs, vol.13, issue.12, pp.720-728, 2015. ,
DOI : 10.2174/138945012803530062
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.1, issue.3, pp.409-425, 2015. ,
DOI : 10.1158/2159-8274.CD-10-0010
SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer, JNCI: Journal of the National Cancer Institute, vol.19, issue.19, 2015. ,
DOI : 10.1158/1078-0432.CCR-13-0884
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies, Clinical Cancer Research, vol.21, issue.23, pp.5235-5279, 2015. ,
DOI : 10.1158/1078-0432.CCR-15-0180
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy, JAMA Oncology, vol.3, issue.4, pp.516-538, 2017. ,
DOI : 10.1001/jamaoncol.2016.5383
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells, Cancer Res, vol.63, issue.1, pp.196-206, 2003. ,
Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression, Cancer Research, vol.69, issue.12, pp.5057-64, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-4287
Activation of Akt-1 (PKB-??) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor Invasion, Cancer Research, vol.64, issue.9, pp.3171-3179, 2004. ,
DOI : 10.1158/0008-5472.CAN-03-3465
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial???mesenchymal transition, The Journal of Cell Biology, vol.267, issue.6, pp.1023-1057, 2005. ,
DOI : 10.1126/science.286.5445.1741
AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation, Cancer Research, vol.76, issue.6, pp.1451-62, 2016. ,
DOI : 10.1158/0008-5472.CAN-15-1941
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep, p.44244, 2017. ,
Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment, European Journal of Cancer and Clinical Oncology, vol.24, issue.9, pp.1445-55, 1988. ,
DOI : 10.1016/0277-5379(88)90335-5
A morphological biosensor for mammalian cells, Nature, vol.366, issue.6455, pp.591-593, 1993. ,
DOI : 10.1038/366591a0
Targeting PI3K/Akt/mTOR Signaling in Cancer, Frontiers in Oncology, vol.13, issue.Suppl 1, p.64, 2014. ,
DOI : 10.1016/j.drup.2009.12.001
Targeting the PI3K signaling pathway in cancer, Current Opinion in Genetics & Development, vol.20, issue.1, pp.87-90, 2010. ,
DOI : 10.1016/j.gde.2009.11.002
SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling, British Journal of Cancer, vol.9, issue.8, pp.1154-63, 2017. ,
DOI : 10.1002/ijc.25255
Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma, Oncotarget, vol.7, issue.28, pp.44236-51, 2016. ,
DOI : 10.18632/oncotarget.10005
Akt1 Ablation Inhibits, whereas Akt2 Ablation Accelerates, the Development of Mammary Adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and MMTV-Polyoma Middle T Transgenic Mice, Cancer Research, vol.67, issue.1, pp.167-77, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-3782
PI3K-AKT-mTOR pathway proteins are differently expressed in oral carcinogenesis, Journal of Oral Pathology & Medicine, vol.44, issue.10, pp.746-52, 2016. ,
DOI : 10.1016/j.oraloncology.2007.08.006
El-Naggar AK, and The Cancer Genome Atlas Group Comprehensive genomic characterization of squamous cell carcinoma of the head and neck. TCGA 2nd annual scientific symposium, 2012. ,
Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck, Oral Oncology, vol.51, issue.4, pp.291-299, 2015. ,
DOI : 10.1016/j.oraloncology.2014.11.012
Targeting FAK Radiosensitizes 3-Dimensional Grown Human HNSCC Cells Through Reduced Akt1 and MEK1/2 Signaling, International Journal of Radiation Oncology*Biology*Physics, vol.83, issue.5, pp.669-76, 2012. ,
DOI : 10.1016/j.ijrobp.2012.01.065
Interaction between hypoxia, p.1 ,
, signaling in HNSCC and NSCLC: implications for future treatment strategies, Future science OA, vol.2, issue.1, p.84, 2016.
AKT can modulate the <i>in vitro</i> response of HNSCC cells to irreversible EGFR inhibitors, Oncotarget, vol.8, issue.32, pp.53288-301, 2017. ,
DOI : 10.18632/oncotarget.18395
A novel read-through transcript <i>JMJD7-PLA2G4B</i> regulates head and neck squamous cell carcinoma cell proliferation and survival, Oncotarget, vol.8, issue.2, pp.1972-82, 2017. ,
DOI : 10.18632/oncotarget.14081
Carboxyl-Terminal Modulator Protein Positively Acts as an Oncogenic Driver in Head and Neck Squamous Cell Carcinoma via Regulating Akt phosphorylation, Scientific Reports, vol.71, issue.1, p.28503, 2016. ,
DOI : 10.1158/0008-5472.CAN-11-0128
A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors, Cancer Chemotherapy and Pharmacology, vol.14, issue.Suppl 14, pp.591-599, 2012. ,
DOI : 10.1158/1078-0432.CCR-07-0955
A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.87, issue.3, pp.479-86, 2013. ,
DOI : 10.1016/j.ijrobp.2013.06.2043
A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer, Cancer, vol.30, issue.suppl, pp.1823-1854, 2013. ,
DOI : 10.1128/JVI.00487-12
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review), International Journal of Oncology, vol.48, issue.3, pp.869-85, 2016. ,
DOI : 10.3892/ijo.2015.3306
Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells, Scientific Reports, vol.5, issue.1, p.42127, 2017. ,
DOI : 10.1093/nar/gkm407
Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage, Scientific Reports, vol.70, issue.1, p.33495, 2016. ,
DOI : 10.1016/S0024-3205(01)01454-0
Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19???784 Diverse Solid Tumors, JAMA Oncology, vol.2, issue.12, pp.1565-73, 2016. ,
DOI : 10.1001/jamaoncol.2016.0891
Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Molecular cancer research : MCR, pp.571-82, 2014. ,